Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics is expected to see strong growth and potential for sustained sales growth through their expanding presence in the high-growth medical device market, solid and increasing operating margins, strong brand reputation and market presence, and potential for new product launches and M&A opportunities. Risks to their success include execution with new and existing Interventional Technologies products, fluctuations in interventional cardiology and electrophysiology procedure volumes, competition in the Plasma segment, tariffs, and potential cyber vulnerabilities.

Haemonetics is facing challenges in its Plasma business segment due to the loss of its largest customer, CSL Plasma, in FY21. This has led to a decline in sales, earnings, and investor confidence. While the recently announced agreement with CSL Plasma is a positive development, the timing and magnitude of U.S. center conversions are uncertain, leading to a negative outlook on the sales and earnings guidance for FY27. Additionally, the company's past commercial execution stumbles and scrutiny of the Interventional Technologies sub-segment raise concerns about its ability to sustain profitability. Therefore, the company's shift towards a higher margin MedSurg segment and potential for margin expansion may not be enough to offset these challenges in the near term.